Common subcutaneous injection sites: Abdomen Upper arm Thigh Rotate sites weekly to reduce the risk of irritation
During hypoglycaemia, insulin secretion is reduced and glucagon secretion is not inhibited
Introduce new foods slowly
The following table describes GLP-1 receptor agonists, their dosing frequency and key pharmacokinetic parameters: Cautions and Contraindications Adverse Effects Acute pancreatitis (rare) Injection site reactions Gastrointestinal disturbances (nausea, vomiting, diarrhoea dehydration and possible renal impairment) Increase in pancreatic enzymes: lipase and amylase (dulaglutide, tirzepatide and semaglutide) Cholecystitis and cholelithiasis Delayed gastric emptying (semaglutide, exenatide, dulaglutide, tirzepatide (diminishes over time)) Increased heart rate Diabetic retinopathy complications (semaglutide, particularly in insulin-treated patients with known diabetic retinopathy) Interactions GLP-1 receptor agonists do not interact via cytochrome P450 , but delayed gastric emptying may alter drug absorption
Every protein-rich meal is an opportunity to support muscle preservation, recovery, energy levels, and overall health
Semaglutide (Ozempic, Wegovy) has a half-life of approximately 7 days, requiring approximately 5 weeks for 97% clearance from the body after the final injection
